Welcome to the May 2025 edition of our Regulatory Roundup! This month, we bring you the latest updates from key regulatory bodies worldwide, including the Therapeutic Goods Administration (TGA) in Australia, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA).
These updates highlight significant strides in medical regulation, from consultations on in vitro diagnostic (IVD) medical device classifications to advancements in artificial intelligence integration within regulatory processes. Additionally, we provide expert tips to streamline your copy approval processes, ensuring efficiency and compliance.
Stay informed about the latest regulatory changes and how they might impact your work and industry.
🇦🇺 Therapeutic Goods Administration (TGA)
IVD Classification Consultation: The TGA actively seeks stakeholder feedback on proposed changes to in vitro diagnostic (IVD) medical device classifications and definitions. This initiative aims to align Australia’s regulations with the European Regulation 2017/746. Stakeholders have until 23 May 2025 to submit their feedback.
Nitrosamine Impurities Update: On 30 April 2025, the TGA updated its guidelines regarding acceptable intake levels for nitrosamine impurities in medicines. This update aligns with recent changes made by the European Medicines Agency (EMA), ensuring consistency in safety standards.
🇺🇸 U.S. Food and Drug Administration (FDA)
AI Integration in Reviews: The FDA has announced a significant step forward in its regulatory processes by integrating artificial intelligence tools across all its centres. Full integration is expected by 30 June 2025, following a successful generative AI pilot to streamline the drug approval process.
COVID-19 Vaccine Advisory Meeting: An advisory committee meeting is scheduled for 22 May 2025 to discuss and make recommendations on selecting the 2025–2026 formula for COVID-19 vaccines in the U.S. This meeting will play a crucial role in shaping the upcoming vaccination strategy.
🇪🇺 European Medicines Agency (EMA)
Advanced Therapies GMP Revision: On 8 May 2025, the EMA published a concept paper proposing revisions to Part IV guidelines on good manufacturing practice (GMP) specific to advanced therapy medicinal products. This revision aims to enhance the regulatory framework for these innovative therapies.
Data and AI Workplan: In collaboration with the Heads of Medicine Agencies, the EMA has released a joint work plan titled “Data and AI in medicines regulation to 2028.” This strategic document outlines plans to leverage data and artificial intelligence to improve regulatory processes and outcomes.
As we navigate the evolving landscape of medical regulation, it is crucial to stay informed about the latest updates from key regulatory bodies. The May 2025 Regulatory Roundup has highlighted significant TGA, FDA, and EMA developments, showcasing efforts to enhance regulatory frameworks and integrate advanced technologies.
We hope this roundup provides valuable insights and helps you stay ahead in your field. Look for future updates, and don’t hesitate to share your thoughts or questions. Together, we can continue to drive progress and innovation in medical regulation.
Thank you for reading, and stay tuned for next month’s roundup!